The Pharmaceutical Benefits Scheme (PBS) and Therapeutic Goods Administration (TGA) have asked that AMA members be made aware of the following updates.
The PBS advises of restriction changes to type 2 diabetes mellitus (T2DM) medicines. T2DM medicines have a change to the PBS authority level and other changes to its restrictions.
The TGA advises of an extension to the Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Fluoxetine) Instrument 2023 (SSSI), which was initially due to expire on 31 May 2024. The SSSI will now remain in force until 30 September 2024 to ensure timely access to the medicine for patients.